NEW HAVEN, Conn., May 15, 2009 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the three months ended March 31, 2009. For the first quarter of 2009, the Company reported a net loss of $6.7 million, compared to a net loss of $6.0 million in the same quarter last year. Cash and cash equivalents and marketable securities at March 31, 2009 were $27.1 million.
